HK Stock MarketDetailed Quotes

01513 LIVZON PHARMA

Watchlist

27.500
+0.100+0.36%

Not Open Dec 30 16:08 CST

25.06BMarket Cap11.16P/E (TTM)

LIVZON PHARMA Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q9)Sep 30, 2024

(Q6)Jun 30, 2024

(Q3)Mar 31, 2024

(FY)Dec 31, 2023

(Q9)Sep 30, 2023

(Q6)Jun 30, 2023

(Q3)Mar 31, 2023

(FY)Dec 31, 2022

(Q9)Sep 30, 2022

(Q6)Jun 30, 2022

Turnover

-5.94%9.08B

-6.09%6.28B

-4.99%3.24B

-1.58%12.43B

1.76%9.65B

6.15%6.69B

-1.90%3.41B

4.69%12.63B

1.27%9.49B

1.08%6.3B

Operating income

-5.94%9.08B

-6.09%6.28B

-4.99%3.24B

-1.58%12.43B

1.76%9.65B

6.15%6.69B

-1.90%3.41B

4.69%12.63B

1.27%9.49B

1.08%6.3B

Operating expenses

10.84%-3.1B

10.99%-2.14B

9.10%-1.15B

-0.09%-4.47B

-6.42%-3.48B

-9.61%-2.4B

-7.03%-1.26B

-4.90%-4.46B

-2.16%-3.27B

-3.14%-2.19B

Gross profit

-3.17%5.98B

-3.35%4.14B

-2.58%2.1B

-2.49%7.96B

-0.70%6.17B

4.30%4.29B

-6.46%2.15B

4.58%8.17B

0.81%6.22B

0.01%4.11B

Selling expenses

12.73%-2.46B

11.57%-1.74B

9.20%-876.11M

7.44%-3.6B

3.03%-2.81B

-3.35%-1.97B

12.80%-964.91M

-0.09%-3.89B

5.97%-2.9B

6.92%-1.9B

Administrative expenses

2.95%-472.58M

-6.43%-330.94M

-28.75%-192.68M

0.39%-654.27M

12.23%-486.96M

12.38%-310.93M

24.94%-149.65M

1.10%-656.86M

-13.81%-554.79M

-22.34%-354.87M

Research and development expenses

25.49%-734.49M

19.67%-490.66M

23.52%-238.17M

6.44%-1.33B

-0.72%-985.76M

-10.15%-610.78M

-8.00%-311.41M

-24.51%-1.43B

-24.48%-978.75M

-9.40%-554.52M

Profit from asset sales

-85.45%-370.4K

76.71%-76.44K

--306.57K

-119.80%-170.44K

-117.81%-199.73K

35.71%-328.23K

----

-87.77%860.66K

18.83%1.12M

-260.99%-510.52K

Revaluation surplus

86.90%-5.5M

43.33%-18.39M

105.96%1.55M

65.92%-25.65M

46.35%-41.99M

63.45%-32.45M

51.49%-25.95M

-226.89%-75.27M

-383.80%-78.27M

-355.14%-88.78M

-Changes in the fair value of other assets

86.90%-5.5M

43.33%-18.39M

105.96%1.55M

65.92%-25.65M

46.35%-41.99M

63.45%-32.45M

51.49%-25.95M

-226.89%-75.27M

-383.80%-78.27M

-355.14%-88.78M

Impairment and provision

51.86%-61.12M

38.68%-32.35M

15.15%-9.74M

-164.17%-323.1M

2.09%-126.95M

-72.01%-52.76M

-154.10%-11.48M

-90.17%-122.31M

-188.35%-129.66M

17.53%-30.67M

-Other impairment is provision

51.86%-61.12M

38.68%-32.35M

15.15%-9.74M

-164.17%-323.1M

2.09%-126.95M

-72.01%-52.76M

-154.10%-11.48M

-90.17%-122.31M

-188.35%-129.66M

17.53%-30.67M

Special items of operating profit

-29.88%119.09M

-51.94%73.54M

-45.08%44.37M

17.21%266.6M

12.19%169.85M

28.50%153.02M

8.80%80.8M

-23.59%227.46M

-28.92%151.39M

-21.57%119.08M

Operating profit

27.66%2.26B

10.65%1.53B

8.89%794.38M

2.97%2.14B

9.41%1.77B

12.80%1.39B

6.41%729.54M

-5.24%2.08B

-12.55%1.62B

-8.72%1.23B

Financing cost

-74.63%54.93M

87.18%77.59M

522.72%54.51M

1.02%271.5M

-14.83%216.48M

-56.60%41.45M

-76.92%8.75M

283.72%268.76M

946.30%254.17M

281.83%95.51M

Special items of earning before tax

26.66%-12.56M

23.33%-3.88M

-55.83%-4.45M

-62.17%-32.44M

-152.29%-17.13M

-96.25%-5.06M

-1,081.96%-2.85M

6.08%-20.01M

-2.91%-6.79M

-178.18%-2.58M

Earning before tax

16.89%2.3B

13.00%1.61B

14.82%844.44M

2.24%2.38B

5.59%1.97B

7.62%1.42B

1.61%735.44M

3.78%2.33B

-0.13%1.87B

-3.54%1.32B

Tax

-3.23%-356.96M

-1.76%-253.69M

-5.58%-128.36M

-29.36%-485.07M

-13.19%-345.79M

-21.57%-249.3M

-7.91%-121.58M

-27.72%-374.97M

-19.42%-305.49M

-7.15%-205.07M

After-tax profit from continuing operations

19.80%1.95B

15.38%1.35B

16.65%716.08M

-2.96%1.9B

4.10%1.62B

5.06%1.17B

0.45%613.86M

0.18%1.96B

-3.24%1.56B

-5.28%1.12B

Earning after tax

19.80%1.95B

15.38%1.35B

16.65%716.08M

-2.96%1.9B

4.10%1.62B

5.06%1.17B

0.45%613.86M

0.18%1.96B

-3.24%1.56B

-5.28%1.12B

Minority profit

1,099.85%273.16M

365.13%183.73M

238.80%108.26M

-221.40%-56.05M

-57.47%22.77M

-60.48%39.5M

-44.75%31.95M

-73.83%46.17M

-66.50%53.53M

-14.79%99.96M

Profit attributable to shareholders

4.44%1.67B

3.21%1.17B

4.45%607.82M

2.32%1.95B

6.29%1.6B

11.50%1.13B

5.17%581.91M

7.53%1.91B

3.72%1.51B

-4.23%1.02B

Basic earnings per share

5.23%1.81

4.10%1.27

4.84%0.65

2.94%2.1

6.83%1.72

11.93%1.22

5.08%0.62

7.37%2.04

3.87%1.61

-4.39%1.09

Diluted earnings per share

5.23%1.81

4.10%1.27

4.84%0.65

2.94%2.1

6.83%1.72

11.93%1.22

5.08%0.62

7.37%2.04

3.87%1.61

-4.39%1.09

Currency Unit

CNY

Accounting Standards

CAS (2007)

Audit Opinions

Unqualified Opinion

Auditor

Grant Thornton Certified Public Accountants (Special General Partnership)

	(Q9)Sep 30, 2024	(Q6)Jun 30, 2024	(Q3)Mar 31, 2024	(FY)Dec 31, 2023	(Q9)Sep 30, 2023	(Q6)Jun 30, 2023	(Q3)Mar 31, 2023	(FY)Dec 31, 2022	(Q9)Sep 30, 2022	(Q6)Jun 30, 2022
Turnover	-5.94%9.08B	-6.09%6.28B	-4.99%3.24B	-1.58%12.43B	1.76%9.65B	6.15%6.69B	-1.90%3.41B	4.69%12.63B	1.27%9.49B	1.08%6.3B
Operating income	-5.94%9.08B	-6.09%6.28B	-4.99%3.24B	-1.58%12.43B	1.76%9.65B	6.15%6.69B	-1.90%3.41B	4.69%12.63B	1.27%9.49B	1.08%6.3B
Operating expenses	10.84%-3.1B	10.99%-2.14B	9.10%-1.15B	-0.09%-4.47B	-6.42%-3.48B	-9.61%-2.4B	-7.03%-1.26B	-4.90%-4.46B	-2.16%-3.27B	-3.14%-2.19B
Gross profit	-3.17%5.98B	-3.35%4.14B	-2.58%2.1B	-2.49%7.96B	-0.70%6.17B	4.30%4.29B	-6.46%2.15B	4.58%8.17B	0.81%6.22B	0.01%4.11B
Selling expenses	12.73%-2.46B	11.57%-1.74B	9.20%-876.11M	7.44%-3.6B	3.03%-2.81B	-3.35%-1.97B	12.80%-964.91M	-0.09%-3.89B	5.97%-2.9B	6.92%-1.9B
Administrative expenses	2.95%-472.58M	-6.43%-330.94M	-28.75%-192.68M	0.39%-654.27M	12.23%-486.96M	12.38%-310.93M	24.94%-149.65M	1.10%-656.86M	-13.81%-554.79M	-22.34%-354.87M
Research and development expenses	25.49%-734.49M	19.67%-490.66M	23.52%-238.17M	6.44%-1.33B	-0.72%-985.76M	-10.15%-610.78M	-8.00%-311.41M	-24.51%-1.43B	-24.48%-978.75M	-9.40%-554.52M
Profit from asset sales	-85.45%-370.4K	76.71%-76.44K	--306.57K	-119.80%-170.44K	-117.81%-199.73K	35.71%-328.23K	----	-87.77%860.66K	18.83%1.12M	-260.99%-510.52K
Revaluation surplus	86.90%-5.5M	43.33%-18.39M	105.96%1.55M	65.92%-25.65M	46.35%-41.99M	63.45%-32.45M	51.49%-25.95M	-226.89%-75.27M	-383.80%-78.27M	-355.14%-88.78M
-Changes in the fair value of other assets	86.90%-5.5M	43.33%-18.39M	105.96%1.55M	65.92%-25.65M	46.35%-41.99M	63.45%-32.45M	51.49%-25.95M	-226.89%-75.27M	-383.80%-78.27M	-355.14%-88.78M
Impairment and provision	51.86%-61.12M	38.68%-32.35M	15.15%-9.74M	-164.17%-323.1M	2.09%-126.95M	-72.01%-52.76M	-154.10%-11.48M	-90.17%-122.31M	-188.35%-129.66M	17.53%-30.67M
-Other impairment is provision	51.86%-61.12M	38.68%-32.35M	15.15%-9.74M	-164.17%-323.1M	2.09%-126.95M	-72.01%-52.76M	-154.10%-11.48M	-90.17%-122.31M	-188.35%-129.66M	17.53%-30.67M
Special items of operating profit	-29.88%119.09M	-51.94%73.54M	-45.08%44.37M	17.21%266.6M	12.19%169.85M	28.50%153.02M	8.80%80.8M	-23.59%227.46M	-28.92%151.39M	-21.57%119.08M
Operating profit	27.66%2.26B	10.65%1.53B	8.89%794.38M	2.97%2.14B	9.41%1.77B	12.80%1.39B	6.41%729.54M	-5.24%2.08B	-12.55%1.62B	-8.72%1.23B
Financing cost	-74.63%54.93M	87.18%77.59M	522.72%54.51M	1.02%271.5M	-14.83%216.48M	-56.60%41.45M	-76.92%8.75M	283.72%268.76M	946.30%254.17M	281.83%95.51M
Special items of earning before tax	26.66%-12.56M	23.33%-3.88M	-55.83%-4.45M	-62.17%-32.44M	-152.29%-17.13M	-96.25%-5.06M	-1,081.96%-2.85M	6.08%-20.01M	-2.91%-6.79M	-178.18%-2.58M
Earning before tax	16.89%2.3B	13.00%1.61B	14.82%844.44M	2.24%2.38B	5.59%1.97B	7.62%1.42B	1.61%735.44M	3.78%2.33B	-0.13%1.87B	-3.54%1.32B
Tax	-3.23%-356.96M	-1.76%-253.69M	-5.58%-128.36M	-29.36%-485.07M	-13.19%-345.79M	-21.57%-249.3M	-7.91%-121.58M	-27.72%-374.97M	-19.42%-305.49M	-7.15%-205.07M
After-tax profit from continuing operations	19.80%1.95B	15.38%1.35B	16.65%716.08M	-2.96%1.9B	4.10%1.62B	5.06%1.17B	0.45%613.86M	0.18%1.96B	-3.24%1.56B	-5.28%1.12B
Earning after tax	19.80%1.95B	15.38%1.35B	16.65%716.08M	-2.96%1.9B	4.10%1.62B	5.06%1.17B	0.45%613.86M	0.18%1.96B	-3.24%1.56B	-5.28%1.12B
Minority profit	1,099.85%273.16M	365.13%183.73M	238.80%108.26M	-221.40%-56.05M	-57.47%22.77M	-60.48%39.5M	-44.75%31.95M	-73.83%46.17M	-66.50%53.53M	-14.79%99.96M
Profit attributable to shareholders	4.44%1.67B	3.21%1.17B	4.45%607.82M	2.32%1.95B	6.29%1.6B	11.50%1.13B	5.17%581.91M	7.53%1.91B	3.72%1.51B	-4.23%1.02B
Basic earnings per share	5.23%1.81	4.10%1.27	4.84%0.65	2.94%2.1	6.83%1.72	11.93%1.22	5.08%0.62	7.37%2.04	3.87%1.61	-4.39%1.09
Diluted earnings per share	5.23%1.81	4.10%1.27	4.84%0.65	2.94%2.1	6.83%1.72	11.93%1.22	5.08%0.62	7.37%2.04	3.87%1.61	-4.39%1.09
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)
Audit Opinions	--	--	--	Unqualified Opinion	--	--	--	Unqualified Opinion	--	--
Auditor	--	--	--	Grant Thornton Certified Public Accountants (Special General Partnership)	--	--	--	Grant Thornton Certified Public Accountants (Special General Partnership)	--	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Trending HK Stocks